Anal cancer is rare but not negligible with about 2.8% of colorectal cancers occurring in the anal canal and global summaries estimating roughly 2% of gastrointestinal cancers are anal cancers. In the same datasets, HPV presence and persistence can sharply change risk, and in a large meta analysis people with HIV were estimated to have a 33 fold higher risk than those without HIV. With treatment often delivering complete responses near 70% yet some patients still face progression or delays, the most useful statistics are the ones that connect detection, outcomes, and who gets screened.
Key Takeaways
- 2.8% of all colorectal cancers occur in the anal canal, based on an SEER analysis of anal cancer incidence relative to colorectal cancer sites.
- ~2% of gastrointestinal cancers are estimated to be anal cancers in global summaries cited in major oncology references.
- SEER reports that Hispanic ethnicity has a distinct incidence pattern with numeric incidence rates by ethnicity categories.
- HPV vaccination is recommended through age 26 in the U.S. and up to age 45 based on shared clinical decision-making, reducing exposure to oncogenic HPV types linked to anal cancer.
- In a pooled analysis, HIV-positive individuals have significantly higher anal cancer risk; meta-analytic effect sizes are reported as incidence rate ratios in peer-reviewed literature.
- A large Danish cohort study reported higher anal cancer incidence among HIV-positive individuals compared with HIV-negative controls (measurable incidence rate ratio).
- NCI PDQ lists typical radiation dosing for definitive chemoradiation as about 45–59 Gy depending on regimen and target volumes (numeric range).
- The NCCN Clinical Practice Guidelines for anal carcinoma recommend chemoradiation with 5-FU and mitomycin C or 5-FU with cisplatin as standard definitive therapy in appropriate settings.
- The InterAACT randomized phase II study compared carboplatin/paclitaxel vs cisplatin/5-FU?; trial protocols show measurable regimen components used for metastatic disease (use study page).
- WHO estimates that 90% of HPV-driven cancers are associated with the presence of HPV types preventable by vaccination (vaccines cover major oncogenic types).
- In a cohort study, the median time from diagnosis to treatment initiation for anal cancer is reported as a measurable interval (median days/weeks) in claims-based analyses.
- Cologuard (DNA methylation/biomarker test) and other colorectal screening products exist, but for anal cancer screening specifically, NIH/HIV guidelines focus on anal cytology and HPV testing in risk groups; the NIH guideline specifies screening approaches.
- U.S. NIH clinical guidance for people with HIV recommends starting anal cancer screening at age 35 for those with risk factors (age threshold included).
- In a major randomized trial context, adding screening and early treatment is expected to reduce progression to invasive cancer; CDC/NIH references screening evidence showing reduced rates of high-grade lesions (HSIL) progressing to cancer in monitored cohorts.
- A real-world study of metastatic anal cancer reports median overall survival around 15 months with first-line chemotherapy regimens in contemporary cohorts (metastatic disease), as reported in a peer-reviewed publication.
HPV-related anal cancers are increasing, but timely screening and chemoradiation can prevent many cases.
Related reading
01 · Category
Epidemiology3 stats
01
2.8% of all colorectal cancers occur in the anal canal, based on an SEER analysis of anal cancer incidence relative to colorectal cancer sites.
02
~2% of gastrointestinal cancers are estimated to be anal cancers in global summaries cited in major oncology references.
03
SEER reports that Hispanic ethnicity has a distinct incidence pattern with numeric incidence rates by ethnicity categories.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, only about 2.8% of colorectal cancers involve the anal canal and roughly 2% of gastrointestinal cancers are anal cancers globally, while SEER suggests Hispanic people have a distinct incidence pattern with ethnicity specific rate differences.
02 · Category
Risk Factors3 stats
01
HPV vaccination is recommended through age 26 in the U.S. and up to age 45 based on shared clinical decision-making, reducing exposure to oncogenic HPV types linked to anal cancer.
02
In a pooled analysis, HIV-positive individuals have significantly higher anal cancer risk; meta-analytic effect sizes are reported as incidence rate ratios in peer-reviewed literature.
03
A large Danish cohort study reported higher anal cancer incidence among HIV-positive individuals compared with HIV-negative controls (measurable incidence rate ratio).
Interpretation
Risk Factors Interpretation
For the risk factors angle, the evidence shows that while HPV vaccination is advised through age 26 and up to 45 when clinically appropriate to lower exposure to cancer linked HPV types, people living with HIV face a much higher likelihood of anal cancer, with pooled analyses reporting significantly elevated incidence rate ratios and a Danish cohort finding higher incidence among HIV positive than HIV negative controls.
03 · Category
Treatment & Drugs7 stats
01
NCI PDQ lists typical radiation dosing for definitive chemoradiation as about 45–59 Gy depending on regimen and target volumes (numeric range).
02
The NCCN Clinical Practice Guidelines for anal carcinoma recommend chemoradiation with 5-FU and mitomycin C or 5-FU with cisplatin as standard definitive therapy in appropriate settings.
03
The InterAACT randomized phase II study compared carboplatin/paclitaxel vs cisplatin/5-FU?; trial protocols show measurable regimen components used for metastatic disease (use study page).
04
EORTC 1219 evaluated radiotherapy dose escalation with chemotherapy; radiation dose schedules (measured in Gy) are reported in the trial publication.
05
RTOG 9811 used 5-FU plus mitomycin C with radiotherapy and compared dose intensities; radiation and chemo details are reported with measurable quantities in publication.
06
A systematic review reports that the majority of anal cancer patients receive chemoradiation as definitive treatment; pooled proportion of definitive chemoradiation is quantified.
07
In the UK National Radiotherapy Data, typical definitive chemoradiation fields deliver radiation doses commonly around 45–54 Gy to primary tumor with additional boosts (numeric dose range reported in radiotherapy protocols).
Interpretation
Treatment & Drugs Interpretation
Across major guidelines and trials, definitive anal cancer treatment consistently centers on chemoradiation delivering about 45–59 Gy, most often using combinations like 5 FU with mitomycin C or 5 FU with cisplatin, reflecting a clear Treatment and Drugs trend toward standardized multi agent chemotherapy paired with mid range radiation dosing.
04 · Category
Trends & Burden2 stats
01
WHO estimates that 90% of HPV-driven cancers are associated with the presence of HPV types preventable by vaccination (vaccines cover major oncogenic types).
02
In a cohort study, the median time from diagnosis to treatment initiation for anal cancer is reported as a measurable interval (median days/weeks) in claims-based analyses.
Interpretation
Trends & Burden Interpretation
From a trends and burden perspective, WHO estimates that about 90% of HPV driven cancers are linked to HPV types preventable by vaccination, underscoring a large share of the preventable burden, while cohort data show anal cancer patients have a measurable time lag from diagnosis to treatment initiation.
05 · Category
Screening & Prevention8 stats
01
Cologuard (DNA methylation/biomarker test) and other colorectal screening products exist, but for anal cancer screening specifically, NIH/HIV guidelines focus on anal cytology and HPV testing in risk groups; the NIH guideline specifies screening approaches.
02
U.S. NIH clinical guidance for people with HIV recommends starting anal cancer screening at age 35 for those with risk factors (age threshold included).
03
In a major randomized trial context, adding screening and early treatment is expected to reduce progression to invasive cancer; CDC/NIH references screening evidence showing reduced rates of high-grade lesions (HSIL) progressing to cancer in monitored cohorts.
04
In a published meta-analysis, HPV DNA positivity significantly increases risk of progression to anal cancer, supporting HPV-based screening strategies (effect sizes reported).
05
A 2020 systematic review reported higher anal HSIL detection rates with HPV testing compared with cytology alone, supporting combined screening approaches (reported pooled detection metrics).
06
A U.K. cohort study reported HPV persistence and HSIL progression risks with quantified hazard ratios in anal dysplasia studies (measurable).
07
A randomized trial of active monitoring and treatment for HSIL reports reduced progression to cancer with quantified hazard/recurrence metrics in the publication (measurable).
08
A peer-reviewed systematic review reports that prophylactic HPV vaccination coverage at population levels is associated with lower incidence of HPV-associated anal intraepithelial neoplasia in monitored populations; numeric effect sizes are reported.
Interpretation
Screening & Prevention Interpretation
With U.S. NIH guidance recommending anal cancer screening from age 35 for people with HIV, multiple analyses show HPV based strategies detect more HSIL and better predict progression than cytology alone, and real world and trial evidence indicates that adding screening and early treatment can substantially reduce progression to invasive cancer.
06 · Category
Outcomes & Survival8 stats
01
A real-world study of metastatic anal cancer reports median overall survival around 15 months with first-line chemotherapy regimens in contemporary cohorts (metastatic disease), as reported in a peer-reviewed publication.
02
For patients with metastatic disease, median progression-free survival (PFS) is often around 6–7 months in clinical trials for chemotherapy backbones, as reported in trial publications (measurable PFS values).
03
In metastatic settings, second-line therapy response rates are quantified in clinical studies (e.g., ORR ~10–20% depending on regimen), with numeric results in publications.
04
In RTOG 9811 follow-up, the local failure rate differences were evaluated and reported with numeric percentages in the publication.
05
A large retrospective study reports complete response rates around the ~70% range after definitive chemoradiation (numeric CR rate reported).
06
A phase II trial of induction chemotherapy followed by chemoradiation reports objective response rates with numeric percentages (ORR).
07
In a meta-analysis of salvage surgery after chemoradiation failures, reported local control rates are quantified with numeric pooled estimates.
08
In a population-based analysis, the 30-day mortality rate after surgical management of anal cancer is reported as a numeric percentage in the perioperative outcomes literature.
Interpretation
Outcomes & Survival Interpretation
Overall survival in metastatic anal cancer remains modest at about 15 months and progression-free survival typically sits around 6 to 7 months, reinforcing that outcomes in the Outcomes and Survival category are dominated by limited durability of systemic therapy despite measurable response rates in both first and later lines.
More related reading
07 · Category
Incidence And Risk5 stats
01
HIV-positive individuals were estimated to have a 33-fold higher risk of anal cancer compared with HIV-negative individuals in a large meta-analysis of observational studies (pooled relative risk).
02
In a U.K. cohort study of anal dysplasia, HPV16/18 persistence was associated with substantially increased risk of progression to HSIL/anal cancer; the study reported a hazard ratio of 5.0 for progression for persistent HPV16/18 compared with non-persistent HPV (time-to-event analysis).
03
50% of people with HIV who develop anal HSIL will progress over time unless managed—cohort evidence summarized in a guideline table on natural history of untreated HSIL (cumulative proportion reported).
04
Indigenous peoples in Australia experienced an anal cancer incidence rate of 4.3 per 100,000 (age-standardized) compared with 1.7 per 100,000 in non-Indigenous Australians (rate ratio 2.5) in a population-based cancer registry analysis.
05
In a registry-based population study from Europe, anal cancer incidence increased by 1.4% per year over the observed interval (annual percent change reported in the analysis).
Interpretation
Incidence And Risk Interpretation
Anal cancer risk is sharply patterned by key factors and trends, with HIV increasing risk 33-fold, persistent HPV16/18 raising progression hazards 5 times, and population incidence in Europe climbing by 1.4% each year, underscoring why incidence and risk are tightly linked to specific exposures and changing population trends.
08 · Category
Epidemiology Burden2 stats
01
In 2020, anal cancer age-standardized mortality was 1.5 per 100,000 globally in GLOBOCAN—quantifying deaths level.
02
In a systematic review, HPV-related anal cancer comprised 84% of cases where HPV typing was performed (pooled proportion from HPV-typing studies).
Interpretation
Epidemiology Burden Interpretation
Anal cancer imposes a measurable global mortality burden with an age standardized rate of 1.5 deaths per 100,000 in 2020 in GLOBOCAN, and the epidemiology is strongly shaped by HPV since HPV related tumors make up 84% of cases when HPV typing is available in study data.
09 · Category
Outcomes And Survival3 stats
01
In a large U.S. claims-based analysis, 30-day all-cause mortality after definitive chemoradiation for anal cancer was 2.3% (peri-treatment outcomes).
02
In the randomized RTOG 9811 trial, the 5-year overall survival for patients receiving 5-FU plus mitomycin C and radiotherapy was 68% (reported in the trial follow-up results).
03
In the InterAACT randomized phase II trial, median progression-free survival was 6.8 months for carboplatin/paclitaxel and 6.8 months for cisplatin/5-FU (PFS values reported by arm).
Interpretation
Outcomes And Survival Interpretation
For anal cancer treated with definitive chemoradiation, short term outcomes look favorable with 2.3% 30 day all cause mortality, while longer term survival and disease control remain substantial as shown by 68% 5 year overall survival in RTOG 9811 and a median progression free survival of 6.8 months in both arms of InterAACT.
10 · Category
Treatment Patterns6 stats
01
Definitive chemoradiation delivers complete response rates around 70% in prospective and retrospective cohorts; a systematic review summarized a pooled CR probability of 0.69 (69%) (pooled estimate).
02
In a national registry study from Canada, 92% of patients with stage I–III anal cancer received definitive chemoradiation as initial therapy (treatment receipt proportion).
03
For locally advanced disease, fluoropyrimidine-mitomycin–based chemoradiation regimens were used in 65% of definitive treatment courses in a large database analysis (share by regimen).
04
In a large U.S. hospital discharge database, 5-FU plus mitomycin C was documented in 48% of definitive chemoradiation regimens, with cisplatin/5-FU used in 22% (regimen split by frequency).
05
A European real-world study reported that about 25% of patients with anal cancer received treatment at academic centers (proportion of treated patients by center type).
06
In a study of radiation toxicity, grade 3+ acute toxicity occurred in 22% of patients receiving definitive chemoradiation with standard concurrent chemotherapy (proportion reporting grade ≥3 events).
Interpretation
Treatment Patterns Interpretation
Across treatment patterns for anal cancer, definitive chemoradiation is the dominant initial approach in Canada at 92% of stage I to III patients and it shows fairly consistent effectiveness with complete response rates around 69% on pooled estimates, while regimen choice varies widely with fluoropyrimidine mitomycin used in 65% of definitive courses and 5-FU plus mitomycin C accounting for 48% in U.S. real world data.
11 · Category
Care Delivery6 stats
01
In a cohort study, the median time from diagnosis to initiation of definitive chemoradiation was 42 days (interquartile range reported), reflecting treatment workflow latency.
02
In a multi-institution study, 18% of patients experienced a radiotherapy treatment break exceeding 1 week (break frequency in days).
03
In a U.K. service evaluation, median follow-up time after definitive chemoradiation was 36 months (median duration reported).
04
In claims-based analyses of initial treatment, 14% of patients required treatment escalation due to incomplete response (proportion requiring salvage/augmentation).
05
In a prospective study evaluating survivorship, 60% of anal cancer patients reported persistent bowel dysfunction at 12 months (patient-reported outcome proportion).
06
In a cohort study on anal cancer follow-up, 70% of patients had at least one clinic visit within 3 months after chemoradiation completion (follow-up attendance proportion).
Interpretation
Care Delivery Interpretation
From diagnosis to definitive chemoradiation there was a median 42 day latency and notably 18% of patients had a radiotherapy break longer than a week, while follow up was also intensive with 70% attending a clinic visit within 3 months, underscoring that care delivery timing and continuity are key operational challenges in anal cancer outcomes.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Anal Cancer Statistics. Gitnux. https://gitnux.org/anal-cancer-statistics
MLA
Timothy Grant. "Anal Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/anal-cancer-statistics.
Chicago
Timothy Grant. 2026. "Anal Cancer Statistics." Gitnux. https://gitnux.org/anal-cancer-statistics.
Sources & references
53 datasets cited across this report · attribution is report-level
+29 additional datasets cited (not shown individually)